SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board
- Dr. Möller’s appointment will strengthen SphingoTec capacities to drive global expansion
- SphingoTec develops biomarker tests for critical care settings and markets them on its point of care analyzer, Nexus IB10.
Hennigsdorf/Berlin, Germany, August 23, 2021 –
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces that Dr. Gerald Möller has joined the company’s advisory board as chairman of the board. With over 40 years of experience in diagnostics and life sciences, Dr. Möller will guide the company’s strategic expansion. SphingoTec is a fully integrated diagnostic company that develops innovative biomarkers for critical care settings and makes them available as rapid tests on its point of care analyzer.
Dr. Andreas Bergmann, CEO and founder of SphingoTec said, “We are very pleased to welcome Dr. Möller as chairman of our advisory board. Dr. Möller brings a wealth of knowledge and expertise accumulated throughout a distinguished international career. His perspective and experience will be an invaluable asset as we head into the next phase of our development.”
Dr. Möller takes over the chair of the advisory board from Dr. Ute Kilger who will continue leveraging her skills and experience as member of the advisory board. “I am confident that our combined experience in key areas will play a valuable role in guiding strategic decisions and broadening SphingoTec’s global footprint,” added Dr. Kilger.
Commenting on the appointment, Dr. Gerald Möller said, “I am excited about the opportunity to serve the company now as Chairman of the Advisory Board. The next phase of SphingoTec will be the dynamic commercialization of the innovative Biomarkers. This will include the market entry and expansion in the US and other key countries. I want to thank Dr. Kilger for her enthusiastic service as Chair of the Advisory Board over many years. Her profound insight in protecting our scientific discoveries laid the ground for what is now possible – building a global business. I am looking forward to working with Dr. Bergmann and Dr. Moesslang in making this happen.”
Previously, Dr. Möller spent 23 years at Boehringer Mannheim Group, where he held several senior management positions, including CEO of the worldwide operating Group. Following the company’s acquisition by Roche, Dr. Möller was named Head of Global Development and Strategic Marketing Pharmaceuticals, and a member of Roche’s Executive Committee. He has been an investment advisor at HBM Partners for 12 years and an active board member of many innovative life science companies such as Illumina Inc, B.R.A.H.M.S. AG, MTM Laboratories AG and Morphosys AG. From 2003 to 2016, Dr. Moeller served as Chairman of FIND (Foundation for Innovative New Diagnostics), a product development and implementation partnership financed by the Bill and Melinda Gates Foundation.
About SphingoTec
SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions. SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec’s proprietary biomarkers are made available as sphingotest® microtiter plate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform. SphingoTec’s subsidiary Nexus Dx Inc. (San Diego, CA, USA) produces the tests alongside a broad menu of established and commonly used tests for acute and critical care.
Contact
Ruxandra Lenz
Sr. Manager Marketing and Communications
SphingoTec GmbH
Neuendorfstr. 15 A
16761 Hennigsdorf
Tel. +49-3302-20565-0
press[at]sphingotec.com
www.sphingotec.com
Hennigsdorf, Germany, 23 July 2026 — SphingoTec GmbH announces that its Chief Executive Officer, Deborah Bergmann, will attend the ADLM 2026 Annual Meeting, taking place from July 26 to 30, 2026. During the conference, SphingoTec will engage with current and prospective partners to discuss ongoing collaborations and opportunities to advance innovations in critical care diagnostics. These interactions support SphingoTec’s strategy to expand the clinical and commercial reach of its biomarker portfolio. “ADLM provides an important platform to connect with partners across the diagnostics ecosystem,” said Deborah Bergmann, CEO of SphingoTec. “These discussions align with our commitment to translating biomarker innovation into clinically meaningful solutions for patients in critical care.” About SphingoTec SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com Media Contact: Email: press@sphingotec.com Phone +49-3302-20565-0 SphingoTec GmbH Neuendorfstr. 15A 16761 Hennigsdorf, Germany
• New ELISA sphingotest® penKid® enables widespread measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard laboratory equipment. • Only available test to match SphingoTec’s reference chemiluminescence assay, developed with patented high-sensitivity technology to provide consistent results across platforms. Hennigsdorf/Berlin, Germany, April 28 2026 - SphingoTec GmbH announces the launch of the ELISA sphingotest® penKid®, a new assay designed to make testing of its proprietary biomarker broadly accessible to research laboratories and pharmaceutical partners. Providing ease-of-use and precision, the test facilitates large-scale investigations of human kidney function in both acute and broader clinical research contexts. Responding to growing research interest The launch follows increasing demand from the scientific community to study penKid - a biomarker reflecting the current state of kidney function in critical care environments. While SphingoTec’s high-sensitivity sphingotest® penKid® assay serves as the reference method for clinical research and third-party IVD assays, the assay technology requiring dedicated equipment was not easily adoptable in research laboratories. The new ELISA sphingotest® penKid® now allows researchers worldwide to benefit from SphingoTec’s patented detection technology using standard photometers, extending penKid testing capability to a wider range of laboratories. Proven performance and data continuity The ELISA sphingotest® penKid® has been developed to achieve excellent correlation with SphingoTec’s reference chemiluminescence assay, ensuring consistent, high-quality results across different assay platforms. Both methods share the same underlying technology capable of detecting penKid concentrations in the picomolar range. Thanks to this technology transfer, researchers can rely on the same analytical precision and reliability that supported the clinical studies establishing penKid as a valuable kidney function biomarker. The assay’s robust design and German manufacturing ensure durable consistency and reproducibility. With this research-use ELISA, SphingoTec responds to the increasing availability of non-validated assays and encourages researchers to not compromise assay quality and performance to ensure trustworthy results - since data from non-validated tests may reflect assay limitations rather than the true performance of the penKid biomarker. Complementary approaches for clinical use and scientific exploration SphingoTec pursues its commercial strategy for the biomarker penKid through strategic out-licensing partnerships such as Boditech Med, which has developed an IVDR-certified assay for routine clinical use and rapid diagnostics. The newly launched ELISA sphingotest® penKid® represents a complementary initiative, specifically designed to support high-throughput clinical and translational research. Through this dual approach, SphingoTec reaffirms its commitment to fostering scientific collaboration and promoting the broader exploration of penKid across diverse research settings. “Developing the ELISA sphingotest® penKid® reflects our long-term commitment to improving critical care diagnostics,” said Deborah Bergmann, Managing Director and CEO of SphingoTec GmbH. “Beyond its currently validated clinical applications, we see strong potential for penKid to support research and improve diagnostics in other fields where kidney function is relevant. By encouraging scientists worldwide to incorporate penKid into their studies and clinical programs, we aim to accelerate innovation and advance best-fit diagnostic solutions that ultimately improve patient care.” About SphingoTec SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com Media Contact: Email: press@sphingotec.com Phone +49-3302-20565-0 SphingoTec GmbH Neuendorfstr. 15A 16761 Hennigsdorf, Germany